USP <1151> - Pharmaceutical Dosage Forms

What it says

Pharmaceutical dosage forms are described in terms of their formulation characteristics, intended route of administration and the general quality attributes relevant to each type, providing foundational context that informs how more specific test chapters and monographs apply to a given product.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This chapter functions as general orientation rather than a pass or fail test, helping connect why certain test chapters, such as <711> for solid oral dosage forms or <1724> for semisolids, apply to one dosage form and not another.
• Understanding a dosage form's general characteristics under this chapter often clarifies which combination of more specific chapters, packaging requirements under <659>, performance testing under <671>, needs to be applied together for a complete quality picture.
• A product that blurs the line between two conventional dosage form categories, such as a semisolid with characteristics of both a cream and a gel, may need this chapter's descriptive framework to correctly determine which specific test chapters actually apply.

What inspectors look for

• Whether the combination of specific test chapters applied to a product is appropriate to its actual dosage form characteristics as described in this chapter.
• Whether a product with ambiguous or hybrid dosage form characteristics has a documented rationale for which specific quality chapters were applied.
• Whether quality attributes considered relevant to the dosage form type are consistently addressed across specifications, release testing and stability programs.

Related regulations